Furthermore, our data suggest that Aβ constructs that specifically bind to HSC, either alone or in combination with an approach targeting IFNγ [57] and/or NO [46], might be a potential therapeutic option for the treatment of advanced stages of cirrhosis. This evidence concerns the gene IFNG and Cirrhosis.